Abstract: (Salph or methoxy salph) Co (initiating ligand) catalyze homopolymerizing rac-PO to produce pure highly isotactic PPO and rac-1-butylene oxide to produce pure isotactic poly(butylene oxide). A product is unfractionated isotactic PPO of m-dyad content >81%, normally at least 99%.

Abstract: Heterocycles, e.g., epoxides, are carbonylated at low pressure with high percentage conversion to cyclic, ring expanded products using the catalyst where L is tetrahydrofuran (THF).

Abstract: Methods and reagents for classifying tumors and for identifying new tumor classes and subclasses. Methods for correlating tumor class or subclass with therapeutic regimen or outcome, for identifying appropriate (new or known) therapies for particular classes or subclasses, and for predicting outcomes based on class or subclass. New therapeutic agents and methods for the treatment of cancer.

Abstract: The present invention discloses the use of bacterial IgA1 proteases to treat IgA1 deposition in tissue and organs. Bacterial IgA1 proteases specifically cleave IgA1 molecules and thus provide a means to specifically cleave and remove IgA1 depositions. Accordingly, therapeutic agents for the treatment of diseases characterized by IgA deposition are provided. In particular, therapeutic agents to treat IgA nephropathy, Dermatitis herpetiformis (DH), and Henoch-Schoenlein purpura (HS) are disclosed.

Abstract: The present invention provides novel ?-O-linked glycoconjugates such as ?-O-linked glycopeptides, as well convergent methods for synthesis thereof. The general preparative approach is exemplified by the synthesis of the mucin motif commonly found on epithelial tumor cell surfaces. The present invention further provides compositions and methods of treating cancer using the ?-O-linked glycoconjugates.

Abstract: This invention relates to the screening of nucleic acids. More particularly, the present invention provides a dysfunctional viral genome capable of both expressing libraries of exogenous nucleic acids and selecting the sequences having a predefined characteristic or function within the cell, such as nucleic acids encoding signal peptides, secreted proteins, membrane bound proteins, proteases and drug-resistance proteins. The invention further provides a method and a kit for selecting nucleic acids having a desired feature, wherein production of a viral particle is dependent on insertion of an exogenous nucleic acid having the desired feature into a dysfunctional viral genome or into a viral genome exposed to a substance inhibiting viral packaging function(s).

Abstract: The present invention provides novel alkaloid compounds and collections of these compounds, and provides methods for the synthesis of these compounds using biomimetic synthetic strategies. Additionally, the present invention provides pharmaceutical compositions and methods for treating disorders such as bacterial infections, proliferative diseases, and reproductive disorders, to name a few.

Abstract: The present invention provides a novel chimeric peptide containing an opioid peptide moiety and a nociceptive peptide moiety for producing analgesia.

Abstract: The invention relates to compounds of the general formula (and pharmaceutically acceptable derivatives thereof): in which RA, RB, RC, RD, R5, R7, R9, R9a, AK, p, q, r and X are as defined herein, and to their preparation and use.

Abstract: This invention relates to compounds of the general formula: in which RA, RB, RC and RD are as defined herein, and to their preparation and use.

Abstract: Muscle cells and methods for using the muscle cells are provided. In one embodiment, the invention provides transplantable skeletal muscle cell compositions and their methods of use. In one embodiment, the muscle cells can be transplanted into patients having disorders characterized by insufficient cardiac function, e.g., congestive heart failure, in a subject by administering the skeletal myoblasts to the subject. The muscle cells can be autologous, allogeneic, or xenogeneic to the recipient.

Abstract: The present invention provides an improved system for detecting the presence or level of an analyte in a sample. In “competition-like” assays of the present invention, a sample including an analyte is mixed with a second ligand to which the analyte binds, and the mixture is exposed to a solid phase containing a first ligand that can compete with the analyte for binding to the second ligand. According to the present invention, the time of exposure of the mixture to the solid phase is limited so that substantially no dissociation of analyte/second ligand complex occurs. The competition-like assays of the present invention are preferably performed with a solid phase containing a substantial excess of first ligand.

Abstract: The present invention provides novel &agr;-O-linked glycoconjugates such as &agr;-O-linked glycopeptides, as well convergent methods for synthesis thereof. The general preparative approach is exemplified by the synthesis of the mucin motif commonly found on epithelial tumor cell surfaces. The present invention further provides compositions and methods of treating cancer using the &agr;-O-linked glycoconjugates.

Abstract: The present invention provides convergent processes for preparing epothilone A and B, desoxyepothilones A and B, and analogues thereof, useful in the treatment of cancer and cancer which has developed a multidrug-resistant phenotype. Also provided are intermediates useful for preparing said epothilones.

Abstract: The present invention provides nucleotide sequences encoding human LTC4 synthase or variants thereof, which nucleotide sequences include a human LTC4 synthase genomic clone, and unique fragments thereof. The present invention also provides recombinant plasmids, and cells transformed therewith, including the LTC4 synthase gene sequences. The present invention further provides the chromosomal localization of the human LTC4 synthase gene, and also provides methods for identifying LTC4 synthase gene mutations that correlate with susceptibility to bronchial asthma. Diagnostic methods are also provided, as are methods for identifying LTC4 synthase modulators (i.e., compounds that alter the expression and/or activity of LTC4 synthase). The presents invention also provides functional equivalents of the LTC4 synthases, protein, and also methods of identifying LTC4 synthase inhibitors.

Abstract: A hair treatment composition including a non naturally-occurring keratin protein in combination with a hair treatment formula is described. The protein is preferably of human origin and has not been previously cross-linked. The protein is most preferably selected from the group of soluble keratin proteins found in human hair. Preferably, the composition contains one, preferably at least two allelic variants of the protein, most preferably in substantially the same ratio at which they are found in hair of a selected individual. The individual may be selected, for example, on the basis of having appealing hair, of being the future user of the hair treatment composition of other reasons.

Abstract: Novel compounds that are anti-angiogenic or immunosuppressive are described. Also described are methods for determining if an animal is at risk for a disease involving abnormal angiogenesis or an immune reaction resulting in pathology comprising evaluating an aspect of MetAP2 metabolism or structure; methods for identifying agents that are anti-angiogenic or immunosuppressive comprising evaluating the effect of the agent on an aspect of MetAP2 metabolism; methods for treating a cell having an abnormality in metabolism or structure of MetAP2; and methods for treating abnormal angiogenesis or an immune reaction which results in pathology in an animal. Pharmaceutical compositions are also provided.

Abstract: The present invention provides a polymer-linked composition having the structure: wherein RA and RB are each independently a linear or branched chain alkyl or an aryl group; wherein is a polymeric support; wherein L is a linker selected from the group consisting of a single bond; a saturated or unsaturated oligomethylene chain, etc., a 1,4-phenylene; or a 1,4-phenylenemethylene moiety, said moiety being optionally substituted by at least one linear or branched alkyl, alkoxy group etc.; and wherein RC is a linear or branched acyclic, cyclic or multicyclic moiety, said moiety being optionally unsaturated and/or substituted by at least one hydrogen, ORi, alkyl, etc.; wherein Ri is hydrogen, CHO, COORii, or a substituted or unsubstituted linear or branched chain alkyl, etc.; wherein if RC is cyclic, said moiety is optionally aromatic and/or heterocyclic; or if multicyclic, said moiety is optionally a fused multicyclic, fully or partially aromatic and/or heterocyclic.

Abstract: The present invention provides an improved system for the rapid and non-destructive identification of chemical compounds attached to solid supports. In general, the invention provides an identification unit comprising a tag attached to the solid support and a binding partner that interacts specifically and detectably with he tag. In preferred embodiments, the identification unit incorporates the advantages of chemically robust tags and a decoding technique capable of amplification for easy detection and analysis. The present invention further provides a kit comprising a collection of tags capable of attachment to a support and binding partners capable of binding selectively and detectably to the tags, to generate an identification unit for the facile determination of the structure of a compound of interest by determining the reaction history and/or structural characteristics of the compounds that are encoded by the identification unit.

Abstract: The present invention provides a system for analyzing polymer molecules by detecting their effects on an optical agent. Certain preferred embodiments of the invention involve the analysis of polynucleotide molecules through detection of their quenching effects on a fluorescent reporter.